Cryo-EM structure of active GPR65 leadXpro has just elucidated the world’s first structure of a proton-sensing GPCR target.
leadXpro Timeline
Latest updates about leadXpro
2nd Ace Drug Discovery Summit
We are delighted to share the exciting news that Juana Lucia Flores-Candia, esteemed Board Member at leadXpro AG, is set to grace the stage at our forthcoming 2nd Ace Drug Discovery Summit (ADDS) at The Insurance Hall in London on the 20th and 21st of March 2024.Don’t miss the opportunity to be part of the […]
Cumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules against Novel Cancer-Focused GPCR Targets
Cumulus Oncology and leadXpro Announce Collaboration.
Resulting IP will be licensed into a newly created Cumulus company
SCIENTIFIC WEBINAR
Early drug discovery requires an interdisciplinary approach with a sophisticated interplay between empirical methods and rational design. Amongst the different therapeutic modalities, orally available small molecules are a major pillar for safe treatment of acute and chronic diseases.